DE69309047D1 - Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren - Google Patents

Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren

Info

Publication number
DE69309047D1
DE69309047D1 DE69309047T DE69309047T DE69309047D1 DE 69309047 D1 DE69309047 D1 DE 69309047D1 DE 69309047 T DE69309047 T DE 69309047T DE 69309047 T DE69309047 T DE 69309047T DE 69309047 D1 DE69309047 D1 DE 69309047D1
Authority
DE
Germany
Prior art keywords
alkyl
phenyl
inhibitors
group
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69309047T
Other languages
English (en)
Other versions
DE69309047T2 (de
Inventor
Michael Crimmin
William Galloway
Andrew Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207759A external-priority patent/GB9207759D0/en
Priority claimed from GB929226337A external-priority patent/GB9226337D0/en
Priority claimed from GB939300701A external-priority patent/GB9300701D0/en
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE69309047D1 publication Critical patent/DE69309047D1/de
Publication of DE69309047T2 publication Critical patent/DE69309047T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
DE69309047T 1992-04-07 1993-04-05 Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren Expired - Fee Related DE69309047T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929207759A GB9207759D0 (en) 1992-04-07 1992-04-07 Compounds
GB929226337A GB9226337D0 (en) 1992-12-17 1992-12-17 Inhibition of cytokine production
GB939300701A GB9300701D0 (en) 1993-01-15 1993-01-15 Inhibition of cytokine production
PCT/GB1993/000706 WO1993020047A1 (en) 1992-04-07 1993-04-05 Hydroxamic acid based collagenase and cytokine inhibitors

Publications (2)

Publication Number Publication Date
DE69309047D1 true DE69309047D1 (de) 1997-04-24
DE69309047T2 DE69309047T2 (de) 1997-09-11

Family

ID=27266136

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309047T Expired - Fee Related DE69309047T2 (de) 1992-04-07 1993-04-05 Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren

Country Status (7)

Country Link
US (1) US5525629A (de)
EP (1) EP0634998B1 (de)
JP (1) JP3348725B2 (de)
AT (1) ATE150452T1 (de)
AU (1) AU3899193A (de)
DE (1) DE69309047T2 (de)
WO (1) WO1993020047A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9220845D0 (en) * 1992-10-03 1992-11-18 British Bio Technology Vasoactive peptide inhibition
GB2316078B (en) * 1994-01-20 1998-06-03 British Biotech Pharm L-tert-leucine-2-pyridylamide
ES2144819T3 (es) * 1994-01-20 2000-06-16 British Biotech Pharm L-terc-leucina-2-piridilamida.
JP3827324B2 (ja) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
AR002945A1 (es) * 1994-11-15 1998-05-27 Bayer Corp Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
WO1996033991A1 (en) * 1995-04-26 1996-10-31 Sankyo Company, Limited β-NONYLHYDROXAMIC ACID DERIVATIVES
WO1996035712A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
DE69620639T2 (de) * 1995-11-22 2002-10-17 Darwin Discovery Ltd Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
AU711804B2 (en) 1995-11-23 1999-10-21 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DK0871439T3 (da) * 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
AU2213697A (en) * 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
DK0968182T3 (da) * 1996-08-07 2004-08-16 Darwin Discovery Ltd Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet
GB9715962D0 (en) * 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
CA2263932A1 (en) * 1996-08-28 1998-03-05 Yetunde Olabisi Taiwo 1,4-heterocyclic metalloprotease inhibitors
AU734834B2 (en) * 1996-08-28 2001-06-21 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors
PT927183E (pt) * 1996-08-28 2004-12-31 Procter & Gamble Inibidores espirociclicos de metaloproteases
JP3539736B2 (ja) * 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー 基質メタロプロテアーゼインヒビターとしてのホスフィン酸アミド
CZ62899A3 (cs) * 1996-08-28 1999-07-14 The Procter & Gamble Company 1,3-Diheterocyklické metaloproteázové inhibitory
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
BR9712019A (pt) 1996-09-10 1999-08-24 British Biotech Pharm Derivados de cidos hirox-mico citoest ticos
EA001460B1 (ru) * 1996-09-27 2001-04-23 Фармация Энд Апджон Компани β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ
CA2279863A1 (en) * 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
ATE263554T1 (de) * 1997-02-27 2004-04-15 Wyeth Corp N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl,sulfinyl oder sulfonyl)-3-substituierte alkyl-, aryl- oder heteroarylamide als matrixmetalloproteinaseinhibitoren
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
BR9808214A (pt) 1997-03-04 2000-05-16 Monsanto Co Compostos de n-hidróxi 4-sulfonil butanamida
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
AU746158B2 (en) 1997-11-12 2002-04-18 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CA2306460A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2002536373A (ja) 1999-02-08 2002-10-29 ジー・ディー・サール・アンド・カンパニー スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
NZ513831A (en) 1999-03-03 2001-09-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
EA200301116A1 (ru) 2001-05-11 2004-06-24 Фармация Корпорейшн Гидроксаматы ароматических сульфонов и их применение в качестве ингибиторов протеаз
DK1406893T3 (da) 2001-06-15 2007-08-06 Vicuron Pharm Inc Bicykliske pyrrolidinforbindelser
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003243272A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
EP1567142A4 (de) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc Behandlung von lungenzellen mit histondeacetylase-hemmern
US7524938B2 (en) 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
KR20090113908A (ko) 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
JPH05503720A (ja) * 1990-12-03 1993-06-17 セルテック　リミテッド ペプチジル誘導体
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds

Also Published As

Publication number Publication date
WO1993020047A1 (en) 1993-10-14
AU3899193A (en) 1993-11-08
DE69309047T2 (de) 1997-09-11
EP0634998B1 (de) 1997-03-19
JPH07505387A (ja) 1995-06-15
US5525629A (en) 1996-06-11
EP0634998A1 (de) 1995-01-25
JP3348725B2 (ja) 2002-11-20
ATE150452T1 (de) 1997-04-15

Similar Documents

Publication Publication Date Title
DE69309047D1 (de) Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
NO177701C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, hydroksaminsyrebaserte kollagenaseinhibitorforbindelser, samt mellomprodukter til anvendelse i framgangsmåten
YU20094A (sh) Hidrazidi 1-h-indol-3-sirćetne kisleine kao inhibitori spla2
BR9306904A (pt) Composto de dicetopiperazina composição farmacêutica ou veterinária processo para preparar o composto e uso de uma dicetopiperazina
BR9307595A (pt) Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis
HUP0002092A2 (hu) Mátrix metalloproteináz inhibitor aktivitással rendelkező N-hidroxi-2-(alkil-,aril- vagy heteroaril-szulfanil-, szulfinil- vagy szulfonil)-3-szubsztituált alkil-, aril- vagy heteroarilamidok
DK0669968T3 (da) Aniliner som mærkningsmidler til mineralolier
DK249089A (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
ATE163921T1 (de) Azoxycyanbenzol-derivate
PT83725B (pt) Processo para preparacao de novos derivados da 3-oxadiol-beta-carbolina e 3-carboxilato-beta-carbolina e de composicoes farmaceuticas que os contem
DK0678090T3 (da) Piperazinderivater
DE69316380T2 (de) Benzenealkancarbonsäuren für kardiovaskulare krankheiten
DE59711463D1 (de) Verwendung von isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose
MY100206A (en) Certain substituted 3-amino-2-benzoylcyclohex-2- enones
FI940568A0 (fi) Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja
NO933903L (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee